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The neural stem cell niches possess the regenerative capacity to generate new functional neurons in the adult brain, suggesting the
possibility of endogenous neuronal replacement after injury or disease. Huntington disease (HD) is a neurodegenerative disease
and characterized by neuronal loss in the basal ganglia, leading to motor, cognitive, and psychological disabilities. Apparently, in
order to make use of the neural stem cell niche as a therapeutic concept for repair strategies in HD, it is important to understand
the cellular and molecular composition of the neural stem cell niche under such neurodegenerative conditions.This paper mainly
discusses the current knowledge on the regulation of the hippocampal neural stem cell niche in the adult brain and by which
mechanism it might be compromised in the case of HD.
1.AdultNeurogenesis
The renowned Spanish neuroanatomist Cajal stated that
“Once development was ended, the founts of growth and
r e g e n e r a t i o no ft h ea x o n sa n dd e n d r i t e sd r i e du pi r r e -
vocably. In adult centers, the nerve paths are something
ﬁxed and immutable: everything may die, nothing may be
regenerated” [1]. Therefore, it has been believed that no
new neurons are generated in the adult brain and most
of the common central nervous system (CNS) pathologies
accompanied by neuronal loss cannot be restored. Amongst
them are the well-known ones: Parkinson’s disease (PD)
accompanied by the degeneration of dopaminergic neurons
in the substantia nigra, Alzheimer’s disease (AD) with a
neuronal loss in the cerebral cortex and certain subcortical
regions, and Huntington’s disease (HD), which is an inher-
ited disease that degenerates neurons in the basal ganglia.
According to the above-mentioned dogma, the vast majority
of neurons in the mammalian brain are generated during
embryonic development [2, 3]. This statement stands true
for most of the regions of the adult brain. However, this
doctrine ended in 1965 when newly generated neurons
were found in two speciﬁc regions of the adult brain:
the subgranular zone (SGZ) in the dentate gyrus (DG)
generates new granular neurons in granule cell layer (GCL)
of the hippocampus and the subventricular zone (SVZ) of
the lateral ventricle wall that gives rise to new cells that
migrate alongtherostral migratory stream (RMS)tobecome
neurons in the olfactory bulb (OB) [4, 5].
2.Hippocampal Neurogenesis
The hippocampus is a bilateral structure that plays a major
role in processing and storage of new information. In
the hippocampus, stem cells are located along the border
between the granular cell layer (GCL) and the hilus known
as subgranular zone (SGZ), where they produce cluster-
forming precursor cells. From there, neuroblasts migrate
into the GCL and become fully matured functional neurons,2 Neurology Research International
where they extend dendrites into the molecular layer (ML)
and launch mossy ﬁbers to the CA3 region [6, 7]. Following
the principle “do or die”, the survival depends on how
suﬃcientlythe new cells are integrated into the neural circuit
[8–10] .F r o mt h en e u r a ls t e mc e l lt ot h em a t u r en e u r o n ,t h e
cells go through deﬁned steps of division, diﬀerentiation,
migration, and maturation. Using speciﬁc markers, it is
possible to investigate the stage-speciﬁc changes of SGZ
neurogenesis in detail [11, 12]. Further, stem and progenitor
cellsfromadulthippocampusproduceneuronsthatgenerate
action potentials, received functional GABAergic and gluta-
matergic synaptic inputs [13, 14].
3.Neurogenesisinthe SVZ-RMS-OB System
The newborn neurons generated in the OB originate from
thesubventricularzone (SVZ)ofthelateral ventricle(LV).In
theadultbrain,newly generatedSVZyoungneuronsmigrate
along therostral migratory stream (RMS)and proceedto the
OB [15]. These neuronal cells integrate upon their arrival
into the OB as speciﬁc subtypes of interneurons. These
subtypes are GABAergic granule cells, which represent the
majority of the new OB neurons and a very small number
of dopaminergic periglomerular interneurons [16, 17]. The
olfactory granule cells are inhibitory interneurons that make
their dendritic connections to the mitral cells and to the
middle tuftedcells. The periglomerularneuronsprojecttheir
dendrites into the corresponding glomerulus and connect to
the incoming olfactory axons from the sensory epithelium.
It has been shown that these newly formed neurons are
functionally integrated into the synaptic circuitry of the OB
[16, 18, 19].
4.The StemCellNiches inthe AdultBrain
The structural and functional maintenance as well as the
regenerative potential of most organs depend on a local
population of immature cells termed somatic stem cells.
In general, stem cells are placed in deﬁned niches or
microenvironments, in which they remain quiescent, but
where they can be activated to proliferate and to generate
a pool of fast dividing, so-called transient amplifying,
progenitor cells. They generate lineage-speciﬁc precursors,
which migrate towards the ultimate destination where they
undergo diﬀerentiation into an appropriate functionally
mature cell type. In the adult brain, new neurons are
generated from neural stem and progenitor cells in the
hippocampus and in the SVZ-OB system. These neural stem
cells(NSCs)have the capacity toproliferate and to self renew
giving rise to neurons, astrocytes, and oligodendrocytes. At
present, the functional signiﬁcance ofstemcell-derived adult
neurogenesis is still under debate, but most studies indicate
t h a ta d u l tn e u r o g e n e s i si si n v o l v e di nl e a r n i n ga n dm e m o r y
processes [20–22]. In addition, the presence of NSCs in
the adult brain provides the basis for endogenous cell
replacement, which could be developed for future therapies
in neurodegenerative disease such as HD. Thus, stimulation
of endogenous NSC proliferation and functional integration
could compensate neuronal loss. Any therapeutic approach
that targets the endogenous neural stem cell population
requires a fundamental understanding of the molecular
regulation of the stem cell niche, in particular in the case
of a degenerative microenvironment as it is present in
neurodegenerative diseases.
5.RegulationofAdultNeurogenesis
Due to the general recognition and acceptance of adult
neurogenesis, there has been an immense response from the
scientiﬁc community, resulting in a large number of studies
investigating how neurogenesis is regulated. Adult neuroge-
nesis is a complex multistep process. This process includes
proliferation, cell cycle exit, fate determination of adult
neural progenitorsand their diﬀerentiation,maturation, and
ﬁnal integration into the neural circuits [23]. Although the
precise mechanisms that generate new neurons in the adult
brain remain elusive, a range of environmental, behavioral,
genetic, neuroendocrine, neurochemical and growth factors
as well as cytokines have been shown to be involved in
the regulation of adult neurogenesis. A number of stimuli
have been shown to inﬂuence neurogenesis: in an enriched
environment the animals are kept in housing conditions
that are more similar to their natural environment. Such an
enriched condition has given rise to increased neurogenesis
and seems to play a neuroprotective role for newly generated
neurons [24–26]. Similar to enriched environmental condi-
tions, wheel-running physical exercise has also been shown
to boost hippocampal neurogenesis drastically through an
increasing rate of progenitor proliferation [27, 28]. The
animals that were exposed to an enriched environment
and physical exercise showed improved motor skills and
better performance in learning tasks [24, 27]. Stroke is a
pathological situation in which blood supply to the brain
is suddenly disrupted. It has been shown that stroke also
stimulates the generation of new neurons [29]. Epileptic
seizure is another pathological situation, which arises from
the abnormal excitation of neuronal networks in the brain.
This epileptic pathological process has also been shown to
provoke neurogenesis in the adult brain [30].
Besides, it has been shown that neurogenesis in the
hippocampus decreases with aging [31, 32]. Stress is a
physiological response to any kind of unpleasant events that
provoke the hypothalamic pituitary axis (HPA) and raise the
release and circulation of adrenal steroid hormones. Adrenal
steroids may be one of the most important neurochemical
regulators of neurogenesis. An increased plasma level of
c o r t i c o s t e r o n e ,a si ta p p e a r sa sar e a c t i o nt oa p p l i e ds t r e s s ,
has negative eﬀects on hippocampal neurogenesis [33–35].
However, this stress-induced inhibition of neurogenesis can
be prevented by systemic administration of neuropeptides
such as prolactin (PRL) [36].
6.RegulationofAdultNeurogenesisby
Signaling Molecules
Inthemammalian tissue,typicalhomeostasisrequireselabo-
rately balanced interactions between cells and the network ofNeurology Research International 3
secreted proteins. These reciprocal communications involve
various extracellular cytokines acting via speciﬁc cell surface
receptors. When the balance between the cells and the
extracellular communication is dysregulated, pathogenesis
canresult [44]. Growth factors are capableof controlling cel-
lular proliferation, diﬀerentiation, maturation, and survival.
Numerous studies have been carried out to demonstrate
that stem and progenitor cells in the adult brain respond
to growth factors. Intracerebroventricular infusion of epi-
dermal growth factor (EGF) and ﬁbroblast growth factor-2
(FGF-2) increased proliferation in the SVZ of the adult rats
brain [12]. Also insulin-like growth factor-1 (IGF-1) seems
tobeinvolvedintheregulationofadultneurogenesis.Plasma
levels of IGF-1 are increased by exercise, and this promotes
major increases in GCL precursor proliferation [45]. More-
over, other studies have demonstrated that intracerebral
infusion of IGF increases both cell proliferation and neuro-
genesis in hypophysectomized rats [46]. Like IGF-1, vascular
endothelial growth factor (VEGF) also has a stimulatory
eﬀect on neurogenesis [47]. Furthermore, a recent report
demonstratedthatgranulocytecolony-stimulatingfactor(G-
CSF) promotes proliferation of neural progenitors [48].
In contrast, members of the family of transforming
growth factor beta (TGF-beta) are known to inhibit neu-
rogenesis by blocking the proliferation of precursor cells in
the adult brain. Therefore, TGF-betas and their downstream
signaling are at the focus of attention to elucidate their
involvement in adult neurogenesis. Bone morphogenetic
proteins (BMPs) are extracellular signaling molecules that
play diverging roles in neuronal development. Generally, the
BMPmoleculesarecharacterized bytheirantagonisticaction
on neurogenesis. Noggin, for example, is a soluble inhibitor
for the BMP4 signal that promotes neurogenesis by blocking
the BMP4 inﬂuence on stem cell proliferation [49].
7.TransformingGrowthFactors
The TGF gene family expresses a set of structurally and
functionally related polypeptides that include TGF-beta1,
TGF-beta2, TGF-beta3, the bone morphogenetic proteins
(BMPs), and the growth diﬀerentiation factors (GDFs) [50,
51]. The TGF-beta name was coined in the year 1981
becauseofitstransforming eﬀectonratkidneyandﬁbroblast
cell lines [52–54]. TGF-betas have been implicated in cell
proliferation, diﬀerentiation, migration, survival, apoptosis,
extracellular matrix (ECM) formation, angiogenesis, metas-
tasis, tumorogenesis, inﬂammation, and tissue regeneration
[51]. TGF-beta1, TGF-beta2, and TGF-beta3 are the highly
homologous isoforms of TGF-beta molecules. Each of these
three isoform genes encodes an inactive precursor protein.
From the 391-amino-acid precursor form of TGF-beta1, the
C-terminal 112 amino acids comprise the mature protein.
The N-terminal peptide is the prodomain, called the latency
associated peptide (LAP). TGF-beta is secreted as a large
latent complex composed of the active TGF-beta form
covalently bound to LAP, which in turn is bound to a latent
TGF-beta-binding protein (LTBP). Since the LTBP is linked
to the extracellular matrix (ECM), the entire complex is
stored in the extracellular space and provides a source of
readily available ligand. Extracellular serine proteases cleave
theLTBPandreleasetheactiveligandfromLAP[50,55].The
biologicallyactiveformofTGF-betaconsistsofahomodimer
built out of two peptides each in size of 12.5kD, which are
linked through disulﬁde bonds [56, 57].
8.The TGF-BetaSignaling Pathway
The TGF-beta family members bind to their cognate het-
eromeric receptor complex, which consists of two types of
transmembrane serine/threonine kinases known as type I
(TGF-betaRI or ALK) and type II receptors (TGF-betaRII)
[58, 59]. These transmembrane receptors represent two
families of serine/threonine kinase receptors of 53 to 65kD
and 80 to 95kD, respectively. In mammals, ﬁve isoforms
of TGF-betaRI and seven isoforms of TGF-betaRII were
identiﬁed. TGF-betaRIII (betaglycan and endoglin) is an
indirectly signaling mediator which promotes the aﬃnity
of TGF-betaRII for TGF-beta2. In contrast, TGF-beta1 and
TGF-beta3 bind directly to TGF-betaRII, a constitutively
active kinase that leads to dimerization with the type I
receptor and phosphorylation of the glycine-serine (GS)
domain. Phosphorylation of the GS domain activates the C-
terminal kinase domain, which phosphorylates and thereby
activates receptor Smads (homologous proteins to the
Sma and Mad proteins from Caenorhabditis elegans and
Drosophila melanogaster (R-Smads)). Characteristically, all
Smad proteins possess two domains, the MH1 and MH2
(mad homology) domains; the MH1 domain is located on
the amino-terminus and the MH2 domain is located on
the carboxy-terminus. Functionally, the MH1 is involved in
protein-DNA interaction whereas the MH2 is responsible
for the protein-protein interaction. Accordingly TGF-beta
activates the phosphorylation of Smad2 and Smad3, while
BMPs activates the phosphorylation of Smad1, Smad5, and
Smad8. The phosphorylated R-Smads dimerize with Co-
Smad (Smad4) and transloctate to the cell nucleus where
theyexert theirfunctionastranscription factors. [50,51, 60].
TGF-beta1 stimulation leads to the nuclear translocation
of the phosphorylated Smad 2/3 and of the Co-Smad 4
complex that activates the inhibitory I-Smads (Smad6 and
Smad7). These activated I–Smads act as an antagonist for
TGF-betaRI-mediated downstream signal by blocking the
receptor accessibility to R-Smads [50, 51, 60, 61]( Figure 1).
9.TGF-Beta1asa MajorRegulatorof
Adult Neurogenesis
Recently, the role of induced level of TGF-beta1 on adult
neurogenesis has been described. Thus infusion of TGF-
beta1 into the ventricles of the adult rat brain revealed a
reduced amount of proliferating cells in the hippocampus
and in the SVZ. Further, infusion of TGF-beta1 lowered the
number of DCX expressing neuronal precursor in these neu-
rogenic niches. This reduced level of proliferation is strongly
correlated with an increased accumulation of phospho-
Smad2, an eﬀector of TGF-beta signaling in Sox2/GFAP-
expressing cells of SGZ in the TGF-beta1 infused brains [62].4 Neurology Research International
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Figure 1: Schematic Illustration: TGF-beta signaling pathway. TGF-beta ligand binds to TGF-betaRII that activates TGF betaRI and induces
the downstream Smad-mediated signal transduction.
Besides, in an in vitro study, treatment of TGF-beta1 in
the neurosphere cultures reduced the proliferation of stem
cell and progenitor cells and induced a shift to G0 phase
of the cell cycle [62]. Subsequently, a study from the Wyss
Coray group has conﬁrmed these ﬁndings in the brains of
transgenic animals that overexpress TGF-beta1 under the
control of the glial ﬁbrillary acidic protein (GFAP) promoter
in astrocytes [63]. Besides, other reports mainly focused
on the late stages of adult neurogenesis and describe that
TGF-beta1 facilitates neuronal diﬀerentiation and promotes
neuronal survival [64–66].
10.TGF-BetaExpressioninthe Physio-
andPathological Brain
TGF-betas are involved in various physiological and patho-
logical processes in the CNS. All three isoforms of TGF-beta
are expressed within the nervous system, in neurons and in
glial cells [51, 67, 68]. Most of the current knowledge about
the expression of TGF-beta in the CNS comes from studies
of the development. In the adult, TGF-beta2 and TGF-beta3
canbefoundinallareasoftheCNS[51].TGF-beta1iswidely
expressed in the choroid plexus and in the meninges, and
its expression is drastically upregulated, in the CNS during
injury and neurodegeneration [69–72] where it is secreted
predominantly by activated microglial cells[73]. Inaddition,
cultivated neurons and astrocytes have been shown to secret
TGF-beta1 [74].Inbrainpathology,TGF-beta1isinvolvedin
coordinatingtheinﬂammatory responses andbrainrecovery.
TGF-beta1 and TGF-beta2 are also involved in brain-tumor
development and progression, in particular of high-grade
gliomas [51, 75–79].
11.ElevatedTGF-Beta1Leveland
Impaired Neurogenesisin
NeurodegenerativeDisorders
Neurodegenerative disorders are devastating hereditary and
sporadic conditions which are characterized by progressive
loss of neuron structure and function, ultimately leading to
the death of selective neuronal populations in speciﬁc brain
areas. Many neurodegenerative disorders occur as a result
of degeneration of neurons due to the toxicity of protein
aggregation. So far, no promising treatments are available
to eradicate these disease conditions. During past decades,
series of reports have demonstrated impaired neurogenesis
in the brain under degenerative conditions occurring with
diseases such as AD, PD, and HD [40, 80, 81]. Therefore,
understandingtheregulationofneurogenesisindegenerative
brains is of crucial importance for therapeutic intervention.
In most of the neuropathological conditions, it has been
shown that speciﬁcally the inﬂammatory cytokines and their
downstream signaling are altered [82]. For example, while
neurogenesis is impaired in the diseased brain of patients
with AD and HD, the pleiotropic cytokine TGF-beta1
and their downstream signaling components are elevatedNeurology Research International 5
[72, 83]. This alteration in cytokine expression and its
subsequentsignaling cascades might be playing a crucial role
in impaired neurogenesis.
12.Huntington’sDisease
Huntington’s disease (HD) is an inherited autosomal dom-
inant disorder resulting from an expansion of the CAG
repeats within the Huntington gene (HD or HTT) located
on chromosome 4 [84]. Healthy individuals have 10 to 35
CAG segment repeats in the HD gene. Individuals with
36 to 40 CAG repeats may or may not develop the signs
and symptoms of Huntington’s disease, while people with
more than 40 repeats have an almost 100% possibility to
develop the disorder [85, 86]. The huntingtin protein has
very rare homology to other proteins and its functions are
poorly understood.The expansionoftheCAG repeatscauses
polyglutamine stretches in the huntingtin protein inducing
progressive neurodegeneration [87]. The dysfunction or loss
o fn e u r o n si nt h eH Db r a i ns t a r t si nt h es t r i a t a lr e g i o n .T h e
striatum is the part of basal ganglia that contains medium
spiny neurons (MSN) [88]. In the HD brain, medium spiny
neurons are most severely aﬀected resulting in atrophy of the
striatum, ﬁrst in the caudate nucleus, then in the putamen.
The second hotspot of neurodegeneration in HD is the
cortex. Neuronsin layersVI and V ofthe cortex projecting to
the striatum are mostly aﬀected. Furthermore, hippocampal
atrophy is typically observed in HD and is correlated with
cognitive deﬁcits and depression presented in HD patients
[89, 90]. As a consequence of neuronal loss in HD, motor
functions and cognition are impaired [91, 92]. Thus far
there are no satisfactory therapies available to alleviate this
devastating disease.
The huntingtin protein is widely expressed within the
bodywiththehighestlevelsinthebrainandthetestis.Within
the brain, the highest levels of expression are found in the
cerebellarcortex,thestriatumandthehippocampus[93,94].
While the direct function of the huntingtin protein is not yet
known, it is apparently required for normal embryogenesis,
since HD knockout animals die at an early developmental
stage [95]. Conditional knockout studies have demonstrated
that the huntingtin protein plays an essential role during
postnatal development, as the inactivation of the HD gene
in the brain and in the testis leads to degeneration of these
two organs [96]. Most importantly, the huntingtin protein
is required for neuronal survival [96–98]. This eﬀect is
most likely mediated through upregulation of brain-derived
neurotrophicfactor(BDNF)expression [99].Arecent report
indicated that the huntingtin protein is localized at spindle
poles during mitosis. Silencin go ft h eH Dg e n ed i s r u p t e dt h e
spindle orientation and promoted neuronal diﬀerentiation
of cortical progenitors in mouse embryos [100] highlighting
the role of huntingtin in neuronal diﬀerentiation.
13.MutantHuntingtinProteinand
IntracellularDysfunctions
In the HD gene, the number of CAG repeats plays a
critical role for its pathogenic activities. More than 40 CAG
repeats in the HD allele deﬁnitively lead to an incorrect
folding of the protein, to loss of function and toxic protein
aggregation. The mechanism of polyglutamine expansion
and its pathogenic roles are unclear. Their direct eﬀect on
theneurodegenerationisstill underdebate,asbothdefensive
and toxic functions have been described. It has been
proposed that misfolded huntingtin aggregates translocate
to the nucleus, where they form neuronal inclusions (NI)
and induce caspase-mediated apoptotic cell death pathways
[101, 102]. NIs may interfere with the expression of genes,
which are essential for neuronal survival signaling pathways.
Recent studies also have shown that mutant huntingtin
proteincan trap someproteins and dislocatethemfrom their
original locations thus interfering or preventing them from
their physiological functions [103]. For example, mutant
huntingtin protein interferes with the function of cAMP
response element-binding (CREB) protein, an important
regulatory molecule that is essential for neuronal survival
[104, 105]. In addition, mutant huntingtin protein interferes
with the ubiquitin proteasome system (UPS), which is
in charge of eradicating ubiquitin tagged misfolded or
dysfunctional proteins by proteolysis [106–108].
14.ExperimentalModelsof
Huntington’s Disease
14.1. Acute Models for Huntington’s Disease. Injection of
aminoacidssuchasN-methyl-D-aspartate(NMDA),quino-
linic acid (QA), or 3-nitro propionic acid (3-NP) leads
to neuronal loss in the desired brain region [109–111].
Even though these models display a robust neuronal loss,
their value is limited since they do not mirror the genetic
component of HD disease. Thus, the following chapter will
focus on some of the genetic models for HD.
14.2. Transgenic Models of Huntington’s Disease. For Hunt-
ington disease, several transgenic models have been devel-
oped in diﬀerent organisms ranging from nematodes to pri-
mates. The nematode Caenorhabditis elegans is the simplest
geneticanimalmodelforpolyglutamine(PolyQ)neurotoxic-
ity. Here, the N-terminal 171 amino acid fragment of human
huntingtin protein containing an expanded polyglutamine
tract is expressed in neurons, where it induces neurodegen-
eration [112]. Also, PolyQ-expressing fruit ﬂies form NIs
and undergo a progressive neurodegeneration [113, 114]. A
major breakthrough in the ﬁeld of HD was achieved with
the developmentof transgenic lines that express the exon1 of
htt with 115 CAG (R6/1) or 155 CAG (R6/2) repeats. These
animals develop progressive behavioural symptoms and an
HD-like neuropathology [115]. They display an early onset
of HD pathology, have a shorter life span, and die within the
ﬁ r s tt w ot of o u rm o n t h so fa g e[ 115]. A yeast artiﬁcial chro-
mosome transgenic mouse model of HD (YAC 128), which
expresses the full-length human mutant HD gene with 128
CAG repeats, also shows neurodegeneration in the striatum
and in the cortex and an HD-like behavior such as motor
and cognitive deﬁcits [116, 117]. Moreover, a transgenic rat
model of Huntington’s disease (tgHD rat) was developed by6 Neurology Research International
Table 1: Adult neurogenesis in HD patients and rodent models.
S.no HD model Neurogenic region Neurogenesis Reference(s)
1 Human Subependymal layer Increased Curtis et al. 2003 [37]
2 QA-lesioned rat Subventricular zone Increased Tattersﬁeld et al. 2004 [38]
3 R6/1 mouse Hippocampus Decreased Lazic et al. 2004 [39]
Gil et al. 2005 [40]
4 R6/2 mouse Hippocampus Decreased Phillips et al. 2005 [41]
Kohl et at. 2007 [42]
5 R6/2 mouse Subventricular zone No Change Phillips et al. 2005 [41]
Kohl et al. 2010 [43]
6 TgHD rat Hippocampus Decreased Kandasamyet al. 2010 [121]
7 R6/2 mouse Olfactory Bulb Decreased Kohl et al. 2010 [43]
8 YAC 128 mouse Hippocampus Decreased Simpsonet al. 2010 [122]
von H¨ orsten and colleagues [118]. This tgHD rat carries a
truncated huntingtin cDNA fragment encoding for 51 CAG
repeats under the control of the rat huntingtin promoter.
The tgHD rats suﬀer from mitochondrial dysfunction and
degeneration of MSNs and show a late onset of motor
deﬁcits, emotional disturbance, and cognitive decline [72,
118–120]. The tgHD rat model permits a detailed analysis of
progressive structural and functional alterations over time.
Moreover, it provides a window of opportunity to examine
the impact of any therapeutic attempt.
14.3. Modulation of the Neural Stem Cell Niche and Neuroge-
nesis in Huntington’s Disease. It has been demonstrated that
neurogenesis is impaired in many of the neurodegenerative
diseases. Impaired neurogenesis has been suggested to play
a major role in the disease progression. In Huntington’s
disease, ithas beenshown thatneurogenesis isreducedin the
hippocampus of R6/1 mouse lines [39]b u ti n c r e a s e di nt h e
SVZofchemical-inducedacutemodels[38]andHDpatients
[37]. (Table 1). The underlying molecularand cellularevents
that lead to these diﬀerential alterations in neurogenesis in
the HD brains are not known. Strikingly, the expression of
TGF-beta1andTGF-betasignalingcomponentsiselevatedin
thedegeneratingHDbrain.Therefore,itcanbehypothesized
that TGF-beta1 might be involved in the stem cell niche
remodelling in HD brains.
To investigate the mechanisms that are involved in
impairment or modulation of neural stem cell niche in
HD, the entire processes of neurogenesis has been explored
in the diﬀerent pathological grade of HD using tgHD
rat and R6/2 mouse model. These tgHD models develop
progressive cognitive deﬁcits during the disease progres-
sion suggesting a possible involvement of hippocampal
dysfunction [115, 119]. Recent reports have demonstrated
that impaired progenitor proliferation is associated with an
increase in neural stem cell quiescence in these transgenic
animal models for HD [42, 121]. These observations have
also been conﬁrmed in the hippocampus of the YAC128
HD model [122]( Table 1). The tgHD animals encountered
a disease-associated progressive decline in hippocampal
progenitor proliferation accompanied by an expansion of
the pool of BrdU-label-retaining Sox-2 positive quiescent
stem cells [121]. Recently, it has been revealed that an
elevated level of TGF-beta1 impairs neural progenitor
proliferation and induces neural progenitors to exit the
cell cycle [62]. Although phospho-Smad2, an eﬀector of
TGF-beta signaling, is normally deﬁcient in the stem cell
niche, it gradually accumulates in Sox2/GFAP-expressing
cells of the subgranular zone in the tgHD brains [121].
Moreover, a comparative transcriptome analysis showed that
mRNA expression of TGF-beta1 and its downstream eﬀector
molecules were elevated in the human HD brains [72].
This line of evidence points towards the elevation of TGF-
beta signaling in tgHD hippocampus, thereby providing an
explanation for the reduced NSC proliferation and induced
NSC quiescence (Figure 2).
Interestingly, in the early phase of the pathology (i.e.,
8 month old tgHD rats), the deﬁcit in NSC proliferation
and inducedNSCquiescencewere compensated byincreased
DCX-expressing neuroblast proliferation, which resulted in
an expansion ofthe DCX-expressing cell population. Besides
survival of newly generated cells, the total number of dentate
gyrus neurons and neuronal density were also reduced in
tgHD rats and correlated with weaker pCREB signaling
[121]. Therefore, the reduction in proliferation might, at
least partially, be due to an elevated TGF-beta signaling in
the stem cell niche of tgHD animals. Over all, the eﬀect of
TGF-beta1-mediated signaling seems to becruciallyinvolved
in triggering quiescence of stem cells, as suggested by the
accumulation of pSmad2 in Sox2-positive/GFAP-positive
SGZ cells (1) in tgHD rats and R6/2 mice [121], (2) after
TGF-beta infusion [62], and (3) by the TGF-beta1-induced
cell cycle arrest in neural stem and progenitor cultures [62,
121].
15.TGF-Beta1Signaling asaPotential
MechanismTriggeringStemCellQuiescence
to Preservethe StemCellPool inHD
Thus far, the neurodegenerative process-induced quiescence
of NSCs in the hippocampal stem cell niche has not been
recognized. A number of studies have already examined
cell proliferation in the neural stem cell niche of animalNeurology Research International 7
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Figure 2: Schematic Illustration: The regulation of neural stem cell niche by TGF-beta1 signaling in tgHD rats. In tgHD rats (HD), the
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and is absent or low in the stem cell niche (SGZ: subgranular zone). In tgHD (HD), however, the overall TGF-beta1 signaling is elevated
and in addition, prominent in the stem cell niche, where it accelerates cell cycle exit and NSC quiescence. Thus, inactivation of TGF-beta1
signalingin the stem cell niche might promote NSC proliferation and contribute to neurogenesis.
models of neurodegeneration and reported reduced pro-
genitor proliferation rates. Hence, this proliferative decline
was documented in the R6/1&2 and YAC 128 HD mouse
lines [39, 42, 122], in the transgenic mouse models of PD,
AD, and ALS [123–125]. A reduction in the numbers of
proliferating cells might result from (1) a reduced number
ofcompetent NSCs, (2)a prolonged cell cycle,(3)premature
diﬀerentiation, or (4) a shift of NSCs from the proliferative
status to quiescence stage. The most recent ﬁndings strongly
support the ﬁnal hypothesis, and it is now crucial to
consider the role of TGF-beta1 in the stem cell niche
remodellingand inductionofstemcellquiescenceduringthe
neurodegenerative processes in HD.
Under normal environment, it is proposed that NSCs
limit their mitotic activity and remain mostly in quiescent
stage until a self-renewing cycle is required to main-
tain a steady state pool and to prevent stem cell pool
depletion. Acute CNS lesions, such as stroke, QA, and
6-hydroxydopamine-induced striatal atrophies, apparently
provide a stimulus to support NSCs proliferation, which
is probably in an attempt to compensate for the neuronal
loss [38, 126, 127]. Moreover, a recent observation indicated
that neuroblast migration is redirected from SVZ-RMS-OB
path towards the degenerating striatum of R6/2 mouse [43]
(Table 1). On the other hand, slow progressive neurodegen-
erationoftencompromiseNSCsintheirproliferativeactivity.
However, TGF-beta1-induced NSC quiescence might well
serve as a mechanism to maintain or to preserve the stem
cell pool in the degenerating HD brains. Although the
pathways induced by TGF-beta-leading to NSC quiescence
require further molecular investigation, mechanisms are
likely to be similar to those previously described in diﬀerent
biologicalsystems, in particular in thehematopoieticsystem.
O b s e r v a t i o ni nt h eh e m a t o p o i e t i cs y s t e ms u g g e s t e dt h a t
Pbx1 and Pbx1-dependent genes as well as FoxO3 could
be eﬀectors of the TGF-beta-induced quiescence [128, 129].
FoxO3 is a central stem cell maintenance factor integrating
a plethora of signaling cascades including the IL-2R/STAT
pathway, the TGF-beta/Smad pathway, the PI3K/Akt/mTOR
cascade, and Notch signal and is therefore likely involved in
the signalling leading to neural stem cell quiescence [130,
131].
16.ReactivationofQuiescentStem
Cellsasa RegenerativeTherapyin
Huntington’s Disease
Huntington’s disease is a progressive neurodegenerative
disease for which no complete cure has been established.
There are certain drug-based treatments which mainly target
reducing the severity of certain symptoms associated with8 Neurology Research International
this disease. Tetrabenazine (Xenazine) is the ﬁrst medica-
tion to be prescribed to treat the signs or symptoms of
Huntington’s disease [132, 133]. This medication helps to
reduce the involuntary movements of Huntington’s disease
by metabolizing the amount of dopamine available in the
brain [133, 134]. Also comorbidity of this disease with
depression can be treated with drugs such as ﬂuoxetine,
sertraline, and nortriptyline [135–137]. However, the side
eﬀects of many of these drugs used to treat the symptoms
of Huntington’s disease may result in further complications
rather than cure.
Recent developmentsin gene silencing technologies such
as RNAi and antisense therapy are considered to play a
major role in reducing the expression of the misfolded
huntingtin protein [138–140]. However, these treatments
also have a disadvantage of suppressing the expression of
physiological allele of the HD gene. Cells containing the
mutant huntingtin protein are known to undergo histone
deacetylases-mediated transcriptional dysregulation [104,
141]. HDAC inhibition by HDAC inhibitors might partially
restore the transcriptional loss in the HD brain [141, 142].
None of these drugs, however, oﬀer a promising treatment
as they involve many side eﬀects and their role in eﬀectively
treating this disease still remains debated.
Alternatively, tissue transplantation strategies such as
striatal grafts have been proposed as an approach for striatal
repair in HD [143, 144]. As a result, this striatal graft onto
the brains of transgenic HD R6-lines did not compromise
the complete functional outcomes[145]. Further the tissue
and cell transplantation strategies exhibit graft rejection
problems. Moreover, these transplants may need unique
tropic support which might be not supported by the
microenvironment in the diseased brain.
Taking the above treatment strategies into consideration,
the possibility of endogenous neural stem cells in the stem
cell niche of the adult brain would have the potential to
compensate and recover neural functions that were lost
due to the degenerative processes seen in HD. In the
adult brain hippocampal DG provides the niche for stem
and progenitors cells and eventually produces new neuron
that proposed to compromise the cognitive outcomes. In
the HD pathology, neurodegeneration takes place in the
hippocampal region but it is inadequately characterized. On
other hand, impairment of hippocampal neurogenesis has
beenclearlydemonstrated inmost ofthe models forHD[39,
42, 121, 122]. Thus suggested that there might be a demand
of neurons in the hippocampus and that might have an
inﬂuence on neurogenesis. The stimulation of endogenous
stem cell pool would represent a strategy to promote
regeneration in the HD brains. However, it has been clearly
demonstrated that in tgHDanimal brains, upregulated TGF-
beta1 and its downstream molecules preserve neuronal stem
cells by inducing their quiescent state[121]. Therefore, inac-
tivation of TGF-beta1 signaling speciﬁcally in the quiescent
stem cells in the stem cell niche of the HD brains would
reactivate their proliferation. Eventually, this strategy could
compensatetheneuronalandfunctional lossinHuntington’s
disease. In Huntington’s diseased brain, the striatum is the
most vulnerable region that is encountered with neuronal
dysfunction and neurodegeneration.Persistence of stem cells
and its migration capacity in the SVZ region also have
a huge potential for replacement therapy. Normally, stem
cells proliferate in the SVZ and migrate along the RMS
to the olfactory bulb; there they give rise to functional
neurons. In pathological conditions like HD, the precursor
cells population in the SVZ can be redirected towards
adjacent striatum and has possibility for the compensation
of neuronal loss [41, 43, 146].
17.Conclusion
Recent ﬁndings strongly support a hypothesis that defects in
progenitor proliferation and an induced NSC quiescence are
coordinated by TGF-beta1 signaling in the stem cell niche
of Huntington’s disease. Thus, TGF-beta1 signaling appears
to be a crucial modulator of neurogenesis in HD pathology
and it can be a promising target for endogenous cell-based
regenerative therapy.
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